RNA therapy company Sirnaomics has raised $47m to develop its technology and work on its STP705 product aimed at tackling non-melanoma skin cancer and the reduction of hypertrophic scars. The first part of the firm’s series C round was led by China Resources and Charoen Pokphand joint venture CR-CP Life Sciences Fund, backed by Legend Sky Investment, Rich Yield Capital and Rolling Boulder Investment. It added $22m to the $25m raised during the second stage if the round which was led by Yuexiu New Industrial Investment backed by Sangel Biomedical Venture Capital, HuaKong Equity Investment and Qianhai Shenghui Investment.
RNA therapy company Sirnaomics has raised $47m to develop its technology and work on its STP705 product aimed at tackling non-melanoma skin cancer and the reduction of hypertrophic scars. The second part of the firm’s series C round was led by China Resources and Charoen Pokphand joint venture CR-CP Life Sciences Fund, backed by Legend Sky Investment, Rich Yield Capital and Rolling Boulder Investment. It added $22m to the $25m raised during the first stage if the round which was led by Yuexiu New Industrial Investment backed by Sangel Biomedical Venture Capital, HuaKong Equity Investment and Qianhai Shenghui Investment.